• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

0.9788 +0.0057 (+0.59%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 43,354
Open 0.9700
Bid (Size) 0.9432 (300)
Ask (Size) 0.9853 (900)
Prev. Close 0.9731
Today's Range 0.9700 - 0.9999
52wk Range 0.8127 - 4.190
Shares Outstanding 5,726,750
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
October 06, 2026
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today announced that Robert Bitterman, President and Chief Executive Officer, will present Phio’s INTASYL® siRNA therapeutic platform at The Global Markets... 
Via B2i Digital
News headline image
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
October 06, 2026
Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.com 
Via Newsfile

Performance

52-Week Range 76.6% below 52-week high
0.9788
0.8152W Low 4.1952W High
1 Week 12.6% below 1-week high
0.971W Low 1.121W High

Phio Pharmaceuticals Corp. - Common Stock (PHIO) traded between $0.81 and $4.19 over the past 52 weeks and last traded at $0.98, 76.6% below its 52-week high. Over the past week it ranged between $0.97 and $1.12.

Past 12 Months
-1.2%
-3.1%
-2.1%
-21.1%
-10.2%
-55.5%
1W -$0.01
1M -$0.03
3M -$0.02
6M -$0.26
YTD -$0.11
1Y -$1.22

PHIO was -55.5% over the past year, -21.1% over six months, -10.2% year to date, -1.2% in the last week.

12 Months vs Market
PHIO
-55.5%
DIA
+13.5%
SPY
+19.2%
QQQ
+27.4%
IWM
+17.3%

Over the past 12 months PHIO returned -55.5% versus DIA (Dow) +13.5%, SPY (S&P 500) +19.2%, QQQ (Nasdaq 100) +27.4% and IWM (Russell 2000) +17.3%.

Volume & Liquidity 0.07× 3-mo avg
Today 43,354 3-mo avg 581.4K
1W
107.4K
1M
103.0K
3M
581.4K
6M
374.8K
YTD
1.5M
1Y
1.9M

PHIO most recently traded 43,354 shares against a 3-month average daily volume of 581.4K.

More News

Read More
News headline image
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
October 05, 2026
Via B2i Digital
News headline image
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
October 05, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
September 23, 2026
Via B2i Digital
News headline image
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
September 23, 2026
Via Newsfile
News headline image
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
September 14, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 11, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
August 11, 2026
Via Newsfile
Topics Intellectual Property
News headline image
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
August 06, 2026
Via Newsfile
News headline image
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
July 22, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
July 22, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
July 21, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
July 15, 2026
Via Newsfile
Topics Intellectual Property
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
June 26, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
June 26, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
June 25, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
June 24, 2026
Via Newsfile
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
June 23, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
June 18, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
May 26, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
May 12, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
May 07, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
April 23, 2026
Via Newsfile
News headline image
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
April 13, 2026
Via Newsfile

Frequently Asked Questions

Is Phio Pharmaceuticals Corp. - Common Stock publicly traded?
Yes, Phio Pharmaceuticals Corp. - Common Stock is publicly traded.
What exchange does Phio Pharmaceuticals Corp. - Common Stock trade on?
Phio Pharmaceuticals Corp. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Phio Pharmaceuticals Corp. - Common Stock?
The ticker symbol for Phio Pharmaceuticals Corp. - Common Stock is PHIO on the Nasdaq Stock Market
What is the current price of Phio Pharmaceuticals Corp. - Common Stock?
The current price of Phio Pharmaceuticals Corp. - Common Stock is 0.9788
When was Phio Pharmaceuticals Corp. - Common Stock last traded?
The last trade of Phio Pharmaceuticals Corp. - Common Stock was at 10/09/26 04:00 PM ET
What is the market capitalization of Phio Pharmaceuticals Corp. - Common Stock?
The market capitalization of Phio Pharmaceuticals Corp. - Common Stock is 5.61M
How many shares of Phio Pharmaceuticals Corp. - Common Stock are outstanding?
Phio Pharmaceuticals Corp. - Common Stock has 6M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap